Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Lenalidomide Maintenance in Patients With High Risk AML in Remission

NCT02126553 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT02126553
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02126553 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Lenalidomide Maintenance in Patients With High Risk AML in Remission
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
November 13, 2014
Completion date
November 30, 2021
Enrollment
29 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alkylating agent-related acute myeloid leukemia, secondary acute myeloid leukemia